We are live on ! Find out more
MTNB icon

Matinas BioPharma
MTNB

71 hedge funds and large institutions have $57.1M invested in Matinas BioPharma in 2020 Q4 according to their latest regulatory filings, with 19 funds opening new positions, 11 increasing their positions, 15 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

111% more first-time investments, than exits

New positions opened: 19 | Existing positions closed: 9

64% more capital invested

Capital invested by funds: $34.8M → $57.1M (+$22.3M)

16% more funds holding

Funds holding: 61 → 71 (+10)

0.04% less ownership

Funds ownership: 0.46% → 0.42% (-0.04%)

27% less repeat investments, than reductions

Existing positions increased: 11 | Existing positions reduced: 15

Holders
71
Holders Change
+10
Holders Change %
+16.39%
% of All Funds
1.26%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
19
Increased
11
Reduced
15
Closed
9
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
+$1.13M
2
PFMOSF
Philadelphia Financial Management of San Francisco
California
+$686K
3
SIG
Sargent Investment Group
Maryland
+$609K
4
ECM
ExodusPoint Capital Management
New York
+$582K
5
Millennium Management
Millennium Management
New York
+$362K

Top Sellers

Rank Fund Capital Flow
1
VC
Vivo Capital
California
-$4.47M
2
Two Sigma Investments
Two Sigma Investments
New York
-$1.27M
3
RJFSA
Raymond James Financial Services Advisors
Florida
-$548K
4
Two Sigma Advisers
Two Sigma Advisers
New York
-$385K
5
WIC
Water Island Capital
New York
-$268K
Name Holding Trade Value Shares
Change 		Change in
Stake
RC
51
RegentAtlantic Capital
New Jersey
$27K – – –
NRS
52
Neville Rodie & Shaw
New York
$24K – – –
FDCDDQ
53
Federation des caisses Desjardins du Quebec
Quebec, Canada
$20.8K +$14.2K +306 New
SBWIC
54
Schaper Benz & Wise Investment Counsel
Wisconsin
$19K – – –
EWM
55
Endurance Wealth Management
Rhode Island
$18K – – –
CG
56
Clarus Group
Texas
$17K +$11.1K +240 New
Janney Montgomery Scott
57
Janney Montgomery Scott
Pennsylvania
$14K -$7.87K -170 -45%
BJL
58
Brighton Jones LLC
Washington
$14K – – –
CFS
59
CRA Financial Services
New Jersey
$14K – – –
FAIM
60
Financial Advocates Investment Management
Washington
$14K – – –
FC
61
Fore Capital
New York
$14K – – –
Franklin Resources
62
Franklin Resources
California
$14K – – –
IA
63
IFP Advisors
Florida
$14K +$9.26K +200 New
SCP
64
Sandhill Capital Partners
New York
$14K +$9.26K +200 New
TRCT
65
Tower Research Capital (TRC)
New York
$10K +$6.76K +146 +7,300%
SPIA
66
Steward Partners Investment Advisory
New York
$4K – – –
HFM
67
Hartford Financial Management
Connecticut
$3K – – –
IAIM
68
International Assets Investment Management
Florida
$3K +$1.9K +41 New
UBS Group
69
UBS Group
Switzerland
$2K -$131K -2,830 -99%
SIAG
70
Signet Investment Advisory Group
Rhode Island
$1K +$926 +20 New
BNP Paribas Financial Markets
71
BNP Paribas Financial Markets
France
$34 – – –
RJFSA
72
Raymond James Financial Services Advisors
Florida
– -$548K -14,299 Closed
WIC
73
Water Island Capital
New York
– -$268K -7,000 Closed
Barclays
74
Barclays
United Kingdom
– -$10K -252 Closed
FI
75
FormulaFolio Investments
Michigan
– -$10K -250 Closed
1 2
3
4

MTNB Hedge Fund Activity: Q4 2020 in Review

71 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Matinas BioPharma (MTNB) for Q4 2020, worth a combined $57.1M — up 64% from $34.8M a quarter earlier.

Buyers outnumbered sellers: 19 funds opened new MTNB positions and 9 closed out — a net gain of 10 holders — while 11 added to existing stakes and 15 trimmed.

The largest buyer was Renaissance Technologies, opening a new position worth an estimated $1.13M. The largest seller was Vivo Capital, cutting an estimated $4.47M.

  • 71 institutional investors held Matinas BioPharma (MTNB) as of Q4 2020, up from 61 in Q3 2020.
  • Funds reported $57.1M of Matinas BioPharma stock for Q4 2020, up 64% quarter-over-quarter.
  • 19 funds opened new Matinas BioPharma positions in Q4 2020 and 9 closed out, a net change of +10 holders.
  • The largest Matinas BioPharma buyer in Q4 2020 was Renaissance Technologies, an estimated $1.13M added.
  • The largest Matinas BioPharma seller in Q4 2020 was Vivo Capital, an estimated $4.47M sold.

Based on aggregated 13F filings for Q4 2020.